Lexeo Therapeutics, Inc. Common Stock
LXEOLexeo Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare neurodegenerative diseases. The company leverages gene therapy and other advanced modalities to address unmet medical needs, aiming to improve quality of life for patients with limited treatment options.
Company News
Lexeo Therapeutics reported positive interim Phase I/II data for LX2020, an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. The therapy demonstrated good tolerability across 10 participants, with 93-162% increases in PKP2 protein expression and stabilization or improvement in arrhythmia burden in the majority of particip...
Lexeo Therapeutics announced a research collaboration with Johnson & Johnson to investigate localized cardiac delivery of AAV gene therapy using Impella heart pump technology. The partnership aims to improve the efficacy and safety of gene therapy for genetically mediated cardiovascular diseases by concentrating viral delivery to the heart while ...
Lexeo Therapeutics has priced a public offering and private placement, raising approximately $135 million by selling 15,625,000 shares at $8.00 per share and pre-funded warrants to Balyasny Asset Management.
Lexeo Therapeutics reports positive interim clinical data for LX2006, a gene therapy for Friedreich Ataxia cardiomyopathy, with FDA openness to an accelerated approval pathway and promising results showing cardiac and neurologic improvements.
Lexeo Therapeutics announces positive interim data for its gene therapy candidate LX2006 in treating Friedreich ataxia cardiomyopathy, with participants showing clinically significant improvements in cardiac biomarkers and increased frataxin expression. The company plans to initiate a registrational study by early 2026.
